SmithKline, Finlay Institute of Cuba deal

SmithKline Beecham acquired worldwide rights (outside Cuba) to commercialize the Institute’s vaccine against serogroups B and C of Neisseria meningitidis, a predominant cause of bacterial meningitis. ...